Interaction between PON1 and population density in amyotrophic lateral sclerosis

NeuroReport

Volumn 20, Issue 2, 2009, Pages 186-190

  Diekstra, Frank P ^a   Beleza Meireles, Ana ^a   Leigh, Nigel P ^a   Shaw, Christopher E ^a   Al Chalabi, Ammar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Gene environment interaction; Motor neuron disease; Paraoxonase; Population density

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ORGANOPHOSPHATE; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DETOXIFICATION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; GENE; GENE ENVIRONMENTAL INTERACTION; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; NEUROLOGIC DISEASE; POPULATION DENSITY; PRIORITY JOURNAL; RURAL POPULATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; UNITED KINGDOM; URBAN POPULATION; URBAN RURAL DIFFERENCE; ENVIRONMENT; GENETICS; STATISTICAL MODEL;

AMYOTROPHIC LATERAL SCLEROSIS; ARYLDIALKYLPHOSPHATASE; ENGLAND; ENVIRONMENT; GENOTYPE; HAPLOTYPES; HUMANS; MODELS, STATISTICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION DENSITY; RURAL POPULATION;

EID: 59149100558     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32831af220     Document Type: Article

References (25)

1. Scarmeas N, Shih T, Stern Y, Ottman R, Rowland LP. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002; 59:773-775.
2. Chio′ A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005; 128:472-476.
3. Nelson LM, McGuire V, Longstreth WT, Matkin C. Population-based case- control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000; 151:156-163.
4. Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP. Lead exposure and amyotrophic lateral sclerosis. Epidemiology (Cambridge, Mass) 2002; 13:311-319.
5. Holloway SM, Emery AE. The epidemiology of motor neuron disease in Scotland. Muscle Nerve 1982; 5:131-133.
6. McGuire V, Longstreth WT, Nelson LM, Koepsell TD, Checkoway H, Morgan MS, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol 1997; 145:1076-1088.
7. Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003; 61:750-756.
8. Slowik A, Tomik B, Wolkow PP, Partyka D, Turaj W, Malecki MT, et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 2006; 67:766-770.
9. Mackness B, Durrington P, Mackness M. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13:357-362.
10. Cronin S, Greenway MJ, Prehn JH, Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatr 2007; 78:984-986.
11. Morahan JM, Yu B, Trent RJ, Pamphlett R. A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. Neurotoxicology 2007; 28:532-540.
12. Saeed M, Siddique N, Hung WY, Usacheva E, Liu E, Sufit RL, et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006; 67:771-776.
13. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
14. Davies HG, Richter RJ, Keifer M, Broomfield OA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334-336.
15. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemhlogy 2007; 29:44-48.
16. Kasperaviciute D, Weale ME, Shianna KV, Banks GT, Simpson CL, Hansen VK, et al. Large-scale pathways-based association study in amyotrophic lateral sclerosis. Brain 2007; 130:2292-2301.
17. Office of National Statistics. Population density, 2002-Regional trends [Internet], Islington (United Kingdom): ONS. [cited 2008 February 19] Available from: http://www.statistics.gov.uk/StatBase/ssdafaset.asp?vlnk= 7662&More=Y.
18. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy- Weinberg equilibrium. Am J Hum Genet 2005; 76:887-893.
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
20. Cherki M, Berrougui H, Isabelle M, Cloutier M, Koumbadinga GA, Khalil A. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp Gerontol 2007; 42:815-824.
21. Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 2000; 10:453-460.
22. O'Leary KA, Edwards RJ, Town MM, Boobis AR. Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics 2005; 15:51-60.
23. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68: 1428-1436.
24. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol 1996; 144:207-213.
25. Piegorsch WW, Weinberg CR, Taylor JA. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 1994; 13:153-162.